Alt Advances in Immunology

1. Auflage 2011
ISBN: 978-0-08-047578-3
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 89, 400 Seiten, Web PDF

Reihe: Advances in Immunology

Advances in Immunology, a long established and highly respected publication, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for future research.

Zielgruppe

Academic/professional/technical: Research and professional

Autoren/Hrsg.

Alt, Frederick W.

Inhaltsverzeichnis

1;Cover;1
2;Copyright Page;5
3;Contents;6
4;Contributors;10
5;Chapter 1: Posttranscriptional Mechanisms Regulating the Inflammatory Response;12
5.1;1. Coordinate Regulation of Pro-Inflammatory Proteins;12
5.2;2. Control of mRNA Stability;16
5.3;3. Translational Inhibition;27
5.4;4. Animal Models;30
5.5;5. Clinical Significance;34
5.6;6. Conclusions;36
5.7;Acknowledgments;36
5.8;References;37
6;Chapter 2: Negative Signaling in Fc Receptor Complexes;50
6.1;1. Fc Receptors;51
6.2;2. Positive Signaling by Activating FcRs;55
6.3;3. Negative Signaling by Activating FcRs;61
6.4;4. Negative Signaling by Inhibitory FcRs;71
6.5;5. Conclusion;81
6.6;Acknowledgments;85
6.7;References;85
7;Chapter 3: The Surprising Diversity of Lipid Antigens for CD1-Restricted T Cells;98
7.1;1. Introduction: From Molecules to Functions;98
7.2;2. CD1 Protein Expression on Antigen-Presenting Cells;101
7.3;3. Subcellular Lipid Antigen Processing Pathways;105
7.4;4. 3-Dimensional Structures of CD1-beta2-Microglobulin-Lipid Complexes;113
7.5;5. Microbial Antigens and Infectious Disease;122
7.6;6. Self Antigens, Autoreactivity, and Autoimmune Disease;130
7.7;7. Synthetic Lipid Antigens and Prospects for Immunotherapy;136
7.8;8. Conclusion: Prospects for Immunotherapy;137
7.9;Acknowledgments;139
7.10;References;139
8;Chapter 4: Lysophospholipids as Mediators of Immunity;152
8.1;1. Introduction;152
8.2;2. LPL Synthesis;154
8.3;3. Cell Surface Receptors for LPLs and Their Signaling Pathways;156
8.4;4. Expression of LPA and S1P Receptors by Immune Cells and Their Functions in In Vitro Studies;159
8.5;5. In Vivo Functions of LPLS in Immune Responses and Inflammation;167
8.6;6. Clinical Applications of S1P Receptor Agonists;170
8.7;7. Summary;171
8.8;References;171
9;Chapter 5: Systemic Mastocytosis;180
9.1;1. Introduction;180
9.2;2. Mast Cell Biology;181
9.3;3. Biology of Kit;195
9.4;4. Mastocytosis;204
9.5;5. Prognosis and Predictive Factors;220
9.6;6. Treatment;220
9.7;7. Supportive Care and Long-Term Management;227
9.8;8. Future Therapy;229
9.9;9. Conclusions;231
9.10;Acknowledgment;231
9.11;References;231
10;Chapter 6: Regulation of Fibrosis by the Immune System;256
10.1;1. Introduction;256
10.2;2. Fibrotic Disease Pathogenesis;257
10.3;3. Cellular Mediators of Fibrosis;260
10.4;4. Inflammatory Chemokines that Regulate Fibrosis;272
10.5;5. The Role of Integrins in Regulating the Fibrotic Response;275
10.6;6. Other Potential Targets for Anti-Fibrotic Therapy;279
10.7;7. Conclusions;281
10.8;References;284
11;Chapter 7: Immunity and Acquired Alterations in Cognition and Emotion: Lessons from SLE;300
11.1;1. Introduction;301
11.2;2. Lupus;304
11.3;3. Neuropsychiatric Lupus;306
11.4;4. Mechanisms of NPSLE;307
11.5;5. Mouse Models of NPSLE;309
11.6;6. Peptide Reactivity of DNA-Reactive Antibodies;309
11.7;7. Presence of DWEYS-Reactive Antibodies in Murine and Human SLE;311
11.8;8. Proteins Harboring the D/E W D/E Y S/G Concensus Sequence: Glutamate Receptors;311
11.9;9. Antibody-Mediated Neurotoxicity;313
11.10;10. A Murine Model for Antibody-Mediated Neuronal Death;315
11.11;11. Antibody-Mediated Neurotoxicity in the Amygdala;318
11.12;12. Evidence that Antibodies Are Involved in NPSLE in Patients;319
11.13;13. Anti-Peptide Antibody Activates Prolactin Secretion;320
11.14;14. Anti-Peptide Antibodies and Manifestations of NP-SLE;321
11.15;15. Implications for SLE;321
11.16;16. Implications for Human Pathobiology;322
11.17;References;322
12;Chapter 8: Immunodeficiencies with Autoimmune Consequences;332
12.1;1. Autoimmune Manifestations in Primary Immune Deficiencies: Relevance and Mechanisms;333
12.1.1;1.1. Introduction;333
12.1.2;1.2. Primary Immunodeficiencies Associated with Autoimmunity;333
12.2;2. AIRE, Central Tolerance, and the Pathophysiology of Autoimmune Polyendocrinopathy;335
12.2.1;2.1. Clinical and Immunological Features of APECED;335
12.2.2;2.2. Molecular Genetics of APECED;340
12.2.3;2.3. Cellular Expression of the AIRE Protein;341
12.2.4;2.4. Immunobiology of AIRE;344
12.3;3. Defective AIRE Expression Explains the Pathophysiology of Autoimmunity in Omenn Syndrome;348
12.3.1;3.1. Omenn Syndrome: Clinical and Laboratory Features;348
12.3.2;3.2. Molecular Pathophysiology of Omenn Syndrome;350
12.3.3;3.3. Unraveling the Molecular Basis of Immune-Mediated Damage in Omenn Syndrome: Implications for Other Forms of T Cell Immunodeficiency with Autoimmunity;352
12.4;4. CD4+ CD25+ Regulatory T Cells and the Pathophysiology of IPEX (Immunodysregulation - Polyendocrinopathy - Enteropathy - X-linked);357
12.4.1;4.1. IPEX Syndrome: Clinical and Laboratory Features;357
12.4.2;4.2. The Mouse Model for IPEX;363
12.4.3;4.3. Molecular and Cellular Pathophysiology of IPEX;364
12.5;5. Concluding Remarks;368
12.6;Acknowledgments;370
12.7;References;370
13;Index;382
14;Contents of Recent Volumes;396